$4.10
1.91%
Nasdaq, Jan 17, 10:08 pm CET
ISIN
NL0015436031
Symbol
CVAC
Sector
Industry

CureVac N.V. Stock price

$4.10
+1.23 42.86% 1M
+0.31 8.18% 6M
+0.69 20.23% YTD
+0.30 7.89% 1Y
-17.75 81.24% 3Y
-51.80 92.67% 5Y
-51.80 92.67% 10Y
Nasdaq, Closing price Mon, Jan 20 2025
+0.00 0.00%
ISIN
NL0015436031
Symbol
CVAC
Sector
Industry

Key metrics

Market capitalization $919.65m
Enterprise Value $349.64m
P/E (TTM) P/E ratio 7.46
EV/FCF (TTM) EV/FCF 3.09
EV/Sales (TTM) EV/Sales 0.59
P/S ratio (TTM) P/S ratio 1.54
P/B ratio (TTM) P/B ratio 1.14
Revenue growth (TTM) Revenue growth 1,202.27%
Revenue (TTM) Revenue $595.81m
EBIT (operating result TTM) EBIT $179.96m
Free Cash Flow (TTM) Free Cash Flow $113.23m
Cash position $614.79m
EPS (TTM) EPS $0.55
P/E forward 4.69
P/S forward 1.69
EV/Sales forward 0.64
Short interest 9.51%
Show more

Is CureVac N.V. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,889 stocks worldwide.

CureVac N.V. Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a CureVac N.V. forecast:

3x Buy
50%
2x Hold
33%
1x Sell
17%

Analyst Opinions

6 Analysts have issued a CureVac N.V. forecast:

Buy
50%
Hold
33%
Sell
17%

Financial data from CureVac N.V.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
596 596
1,202% 1,202%
100%
- Direct Costs 192 192
8% 8%
32%
404 404
406% 406%
68%
- Selling and Administrative Expenses 52 52
20% 20%
9%
- Research and Development Expense 145 145
32% 32%
24%
206 206
167% 167%
35%
- Depreciation and Amortization 26 26
15% 15%
4%
EBIT (Operating Income) EBIT 180 180
154% 154%
30%
Net Profit 124 124
139% 139%
21%

In millions USD.

Don't miss a Thing! We will send you all news about CureVac N.V. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

CureVac N.V. Stock News

Positive
Seeking Alpha
13 days ago
CureVac N.V.'s CVGBM vaccine showed positive safety and immunogenicity data in Part A of its phase 1 study for resected glioblastoma, with no dose-limiting toxicities. Key catalysts include Part B CVGBM resectable GBM data release in 2nd half of 2025 and possible phase 2 study initiation in 2nd half of 2026. The company is also developing a vaccine for squamous NSCLC, with an IND filing expecte...
AD HOC NEWS
17 days ago
Nach Millionenverlusten rund um die gescheiterte Entwicklung eines Corona-Impfstoffs fokussiert sich das Tübinger Biotech-Unternehmen Curevac NL0015436031 auf die Forschung.
Positive
MarketBeat
about one month ago
Small-cap stocks often experience outsized gains during bullish markets. Their smaller market capitalizations and growth-oriented profiles make them more sensitive to improving economic conditions, where rising investor confidence drives capital toward higher-risk, higher-reward opportunities.
More CureVac N.V. News

Company Profile

CureVac BV is a clinical-stage biopharmaceutical Company developing tumour immunotherapy. It offers RNA optimization that encode functional proteins that replace defective or missing proteins using the cell's intrinsic translation machinery. The company was founded by Ingmar Hoerr and Florian von der Mülbe in 2000 and is headquartered in Tübingen, Germany.

Head office Netherlands
CEO Alexander Zehnder
Employees 1,172
Founded 2020
Website www.curevac.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today